Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarkers Profile in Provoked Versus Unprovoked Deep Venous Thrombosis.
Tavares IR, Caffaro RA, Portugal MF, Ribeiro CM, da Silva VS, Krupa E, Nikolovski S, de Britto KF, Gomes Pereira Petisco AC, Miranda MC, Gomes de Souza Santos S, da Silva Dourado M, Siqueira PV, Siddiqui F, Fareed J, Ramacciotti E. Tavares IR, et al. Among authors: ramacciotti e. Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241238211. doi: 10.1177/10760296241238211. Clin Appl Thromb Hemost. 2024. PMID: 38566607 Free PMC article.
Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial : Venous thromboembolism prophylAxis after gynecoLogical pElvic cancer surgery with RIvaroxaban versus enoxAparin (VALERIA trial).
Longo de Oliveira ALM, de Oliveira Pereira RF, Agati LB, Ribeiro CM, Kawamura Suguiura GY, Cioni CH, Bermudez M, Pirani MB, Caffaro RA, Castelli V Jr, Resende Aguiar VC, Volpiani GG, Paschoa A, Scarlatelli Macedo AV, de Barros E Silva PGM, de Campos Guerra JC, Fareed J, Lopes RD, Ramacciotti E. Longo de Oliveira ALM, et al. Among authors: ramacciotti e. Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221132556. doi: 10.1177/10760296221132556. Clin Appl Thromb Hemost. 2022. PMID: 36474344 Free PMC article. Clinical Trial.
Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors).
Bonifácio LP, Ramacciotti E, Agati LB, Vilar FC, Silva ACTD, Louzada Júnior P, Fonseca BALD, Souza HCC, Oliveira CCC, Aguiar VCR, Quadros CAA, Dusilek C, Itinose K, Risson R, Ferreira LRR, Lopes RD, Kallas EG, Bellissimo-Rodrigues F. Bonifácio LP, et al. Among authors: ramacciotti e. Rev Soc Bras Med Trop. 2023 Apr 14;56:e0565. doi: 10.1590/0037-8682-0565-2022. eCollection 2023. Rev Soc Bras Med Trop. 2023. PMID: 37075454 Free PMC article. Clinical Trial.
94 results